Improvement of ulcerative lesion of mycosis fungoides by bexarotene
2017 Volume 32 Issue 2 Pages 192-196
Details
2017 Volume 32 Issue 2 Pages 192-196
A 55-year-old man was diagnosed as having mycosis fungoides classified as stage IIB (T3, N0, M0)and had been receiving ultraviolet therapy and electron beam irradiation. Although he achieved remission using this treatment regimen, his skin lesions recurred, and systemic administration of etoposide was initiated. Following a partial response, his skin symptoms gradually worsened, and he presented with multiple deep ulcerations on his skin, including the development of lesions on his right arm. Alternatively, oral bexarotene monotherapy (300 mg/m2/day) was introduced, and he showed an improvement in the ulcerations. Oral bexarotene monotherapy could be an effective treatment option for patients diagnosed with mycosis fungoides, presenting with skin ulcerations refractory to treatment using systemic etoposide.[Skin Cancer (Japan) 2017 ; 32 : 192-196]
